RPG Life Sciences looks to enter India's GLP-1 market

RPG Life Sciences is planning to enter India’s fast-emerging GLP-1 diabetes and obesity drug space, while keeping the US market on a medium-term acquisition-led radar, as it eyes ₹2500 crore turnover by 2030.

- SOHINI DAS

With a new managing director (MD) at the helm, the RPG Group arm is also doubling down on domestic branded formulations, sharpening its specialty focus, apart from building capacities in the active pharmaceutical ingredients (API) space through acquisitions.

“We have created a strategic vision built around five pillars, with building big, scalable brands at the core,” said Ashok Nair, MD, RPG Life Sciences. Nair, a pharma industry veteran having worked in Abbott, Cipla and Torrent Pharma, is consciously stepping away from crowded mass-market therapies to focus on super-specialty segments where clinical depth, complex prescribing behaviour and long treatment cycles support durable branding.

“The promoter vision is clear: To make RPG Life Sciences a flagship company of the group.” Nair told Business Standard.

The firm posted ₹582.1 crore revenue in 2024-2025 (FY25), up 13.5 per cent year-on-year (Yo-Y). In Q2FY26, RPG Life Sciences revenue from operations touched ₹181.7 crore, up 5.5 per cent.